Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
申请人:Pfizer Inc.
公开号:US20030055038A1
公开(公告)日:2003-03-20
The present invention relates to compounds of formula I,
1
and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.
BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS
申请人:Pfizer Products Inc.
公开号:EP1220831B1
公开(公告)日:2005-06-08
US6410736B1
申请人:——
公开号:US6410736B1
公开(公告)日:2002-06-25
US6596741B2
申请人:——
公开号:US6596741B2
公开(公告)日:2003-07-22
[EN] BIARYL ETHER DERIVATIVES USEFUL AS MONOAMINE REUPTAKE INHIBITORS<br/>[FR] DERIVES DE DIARYLETHER UTILISES COMME INHIBITEURS DU RECAPTAGE DE MONOAMINES
申请人:PFIZER PROD INC
公开号:WO2001027068A1
公开(公告)日:2001-04-19
The present invention relates to compounds of formula (I) and to their pharmaceutically acceptable salts. Compounds of formula (I) exhibit activity as serotonin, norepinephrine, and dopanine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.